MicroPort 心通医疗

MicroPort CardioFlow Medtech Corporation

2024 Interim Results Presentation

September 2024

Disclaimer

This presentation was prepared by MicroPort CardioFlow Medtech Corporation (微创心通医疗科技有限公司) (the "Company") solely for use at the presentation for 2024 interim results.

The information contained in this presentation has not been reviewed by any regulatory authority in any jurisdiction nor independently verified. No representation or warranty, expressed or implied, is made and no reliance should be placed on the accuracy, fairness or completeness of the information contained herein. The information and opinions contained in this presentation are provided as of the date of this presentation or the respective cut-off date in respect of the clinical trial data, are subject to change without notice and will not be updated or otherwise revised to reflect any developments, which may occur after the date of the presentation. Neither the Company nor any of its affiliates, advisers or representatives accepts any liability whatsoever for any actual or consequential loss or damages howsoever arising from the provision or use of any information contained in this presentation. The Company may alter, modify or otherwise change in any manner the contents of this presentation, without obligation to notify any person of such alternations, modifications or changes.

This presentation contains statements that constitute forward-looking statements. These statements can be recognized by the use of words such as "expects", "plan", "will", "estimates", "projects", "intends", or words of similar meaning or intent. Such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and actual results may differ from those in the forward-looking statements as a result of various factors and assumptions. The Company has no obligation and does not undertake to revise forward- looking statements contained in this presentation to reflect future events or circumstances. Accordingly, you should not place undue reliance on any forward-looking information.

This presentation is for information purposes only and does not constitute or form part of, and should not be construed as, an offer to sell or issue or the solicitation of an offer to buy or acquire securities of the Company, any of its holding companies, or any of its subsidiaries in any jurisdiction or an inducement to enter into investment activity. No part of this presentation, nor the fact of its distribution, shall form the basis of or be relied upon in connection with any contract, commitment or investment decision whatsoever. Any decision to purchase or subscribe for any securities of the Company should be made after seeking appropriate professional advice. By attending or receiving this presentation you acknowledge that you will be solely responsible for your own assessment of the business, the market and the market position of the Company and that you will conduct your own analysis and be solely responsible for forming your own view of the potential future performance of the business of the Company.

This document does not constitute a prospectus or an offer to the public within the meaning of the Companies (Winding Up and Miscellaneous Provisions) Ordinance of Hong Kong and may only be made available to professional investors within the meaning of the Securities and Futures Ordinance of Hong Kong. The receipt of this document by any recipient is not to be taken as constituting the receipt of investment advice or an establishment of customer or client relationship.

Agenda

Business Highlights

1H24 Highlights: Exceptional Commercialization and Fruitful Pipeline Progress

Key Indicators

Revenue	RMB 223.1mn	+ 26.5%YOY
GPM	70.9%	+ 4.8 pptsYOY
Operating Expenses[1]	90.5%	- 36.9 pptsYOY
Hospitals Covered Globally	700+	+ 77
Net Loss	-57.8mn	- 67.8%YOY

Robust Financials

- **Domestic revenue +26.4%** YOY and **overseas revenue +29.2%** thanks to implementation of effective commercial strategies in expanding hospital coverage
- **Commercial profit +138.4%** due to our efforts in improving GPM and control of the distribution expenses
- **Cash balance**[2] at **RMB 15.6 billion** as of June 30, 2024.

1. *Refers to the total amount of distribution, R&D, and M&A expenses as percentage of revenue;*
2. *Including cash, cash equivalents and time deposits.*

Operational Highlights

- **TAVI hospital coverage:** domestic: **+50** to **over 600**, overseas: **+27** to **~100,** continue to gain shares in top hospitals while cultivating new hospitals
- **VitaFlow Liberty®** received CE Mark and registration in HKSAR, Saudi Arabia, Belarus, Serbia, Malaysia, up to **11** overseas countries and territories
- **Acquisition of CardioAdvent** marks the official expansion of the Group's business into stroke prevention in patients with **nonvalvular** atrial fibrillation
- **AnchorMan ® LAAC and LAAA** enrolled in the online bidding system of almost all the provinces, and completed the first batch commercial applications
- **VitaFlow Liberty ®** registration in emerging markets in progress: Brazil, Korea, Iran, Kazakshtan, Mexico, etc.
- **VitaFlow Liberty® Flex** in the registration process of NMPA
- **Alwide® Plus**, **AnchorMan® LAAC** and **AnchorMan® LAAA** entered the key stages of CE mark registration
- **Self-developed TMVR** completed near **20** human applications, one completed two-year postoperative follow-up which indicated stable artificial valve function
- **AltaValve™** was granted two breakthrough device designations by the FDA, and gained IDE approval from FDA to conduct a new pivotal study
- **Kewei Medical distribution cooperation** enabled the Company to further diversify the product portfolio

Sales & Marketing Review

Healthier Growth Driven by Higher Sales Manpower Efficiency

China: Healthier Growth

- 26.4% ↑ Revenue RMB 215mn
- +50 ↑ Hospital coverage 603
- +53 ↑ Independent physicians 360
- 10.1 ppts ↓ Distribution cost 39.1%

Non-China: Steady Pace

- 29.2% ↑ Revenue RMB 8mn
- +27 ↑ Hospital coverage ~100
- 8 Countries launched
- +7 ↑ Independent physicians ~30

Sales Manpower Efficiency [1]

Note:
1. Sales manpower efficiency equals to revenue divided by the average number of sales personnel of the year;
2. The revenue used for calculating 1H 2024 sales manpower efficiency ratio is annualized revenue

Average Implantation Volume per Sales Person



Continuous Growth Fueled by Further Market Penetration Globally

China: Continuous Efforts in Enhancing Brand Promotion

Continuous efforts for market education and intragroup synergy accelerated our market expansion

Enhanced brand recognition by a series of academic events: China Valve (HangZhou) 2024, OCC 2024, ASCVTS

Effective Commercial Strategies enhanced doctors' acceptance for VitaFlow® series treating AR patients, and speed up promotion in cardiac department

Leveraged seasoned sales and marketing team for selling of LAAC

LAAC was highly recognized by experts during its exposure in various academic seminars with its unique design and clinical performance

Non-China: Carve Out a Unique Position within Global TAVI Market

Overseas expansion led by TAVI: implanted in **6** countries: Argentina, Colombia, Thailand, Russia, Chile, and Switzerland

Created linkage between Chinese and international physicians through the VitaFlow®platform to achieve continuous global promotions (EUR PCR, MICHs-Russia, Proctoring in Russia and Thailand)

Deepened Hospital Coverage: entered into 27 new centers, covered **~100** hospitals accumulatively

More Independent Physicians: ~30 accumulatively, covering 4 countries and regions (Argentina, Colombia, Russia, and Thailand).

Layout International Market and Expand Global Influence

Major Achievements in VitaFlow Liberty®

- **HKSAR,** approved in Q1，to be launched in Q3
- **CE Mark,** approved in Q2
- **Saudi Arabia,** approved in Q2, to be launched in Q3
- **Chile,** launched in Q1
- **Switzerland,** launched in Q3
- **Belarus,** approved in Q3
- **Serbia,** approved in Q3
- **Malaysia,** approved in Q3
- **Azerbaijan,** 1st implantation in preparation
- **Registration in progress:** Brazil, South Korea, Kazakhstan, Iran, Mexico……

Solid Steps Toward Globalization



approved or launched　　registration underway

Product Pipeline Update

Innovative and High-quality Total Solutions for Structural Heart Diseases

All-round Structural Heart Portfolio via In-House R&D and Collaboration with Global Partners

TAVI

2 launched
3 under R&D



- VitaFlow ® and VitaFlow Liberty® were widely used with positive results both in clinical trials and real world
- VitaFlow®III embedded with an innovative steerable retrievable delivery system, NMPA registration in progress
- VitaFlow®IV and VitaFlow® Balloon Expandable in design stage

TMV

2 under R&D

- Inhouse R&D + Collaboration with global partner 4C Medical
- Successful FIM of self-developed TMVR product with positive 2-year follow up, marking the world's first dry-tissue TMVR system with clinical application

TTV

2 under R&D

- 2 replacement products under R&D
- Inhouse R&D + Collaboration with global partner 4C Medical

Procedural Accessories

4 launched
1 Pending approval

- Alwide® Plus balloon catheter CE registration in progress
- AccuSniper™ Double-Layer Balloon Catheter received NMPA approval

Left Atrial Appendage Products

2 launched
1 under R&D



- AnchorMan® LAAC System and Left Atrial Appendage Access System received NMPA approval, CE mark registration in progress
- Next generation LAAC under R&D

VitaFlow® Series: Positive Clinical Trial Results and KOL Endorsements

VitaFlow®

Transcatheter Aortic Valve Implantation System



Relatively lower all-cause mortality rate

1-year follow-up period

0 moderate or severe PVL

5-year follow-up period

81.8% patient survival rate

2-year follow-up period

0 major (disabling) stroke

8-year follow-up period

60.9% patient survival rate

All-Cause Mortality Comparison with Peers

Time	VitaFlow®	Peer I (China)	Peer II (U.S.)
30-day	0.9%	5%	3.3%
1-year	2.7%	6.1%	14.2%
2-year	4.5%	8.9%	22.2%
3-year	10.9%	12.9%	32.9%
4-year	12.7%	14.9%	N/A
5-year	18.2%	34.1%	55.3%
6-year	24.8%	38.2%	N/A
7-year	31.4%	47.73%	N/A
8-year	39.1%	N/A	N/A

VitaFlow Liberty®

Transcatheter Aortic Valve Implantation System



Significantly reduced intraoperative valve-in-valve incidence

Product	VIV Incidence
VitaFlow Liberty®	4.3% (7/163)
VitaFlow®	8.2% (9/110)

During the procedure

100% retrieval success

30-day follow-up period

0 major (disabling) stroke

Note: Please refer to Appendix 2 for full clinical data comparison.

Progress and Upcoming Milestones

- Received CE Mark, registered in Argentina, Columbia, Thailand, Russia, Indonesia, HKSAR, Saudi Arabia, Serbia, Chili, Belarus, and Malaysia
- Registration in progress in emerging markets: Brazil, Korea, Iran, Kazakhstan, Mexico…

VitaFlow® Series: Positive Clinical Trial Results and KOL Endorsements

VitaFlow Liberty® Flex

Transcatheter Aortic Valve Implantation System



Steerable catheter expected to significantly improve patient outcomes won strong KOL endorsements

- Inherit all the advantages of VitaFlow Liberty®
  Provide physicians with excellent ease-of-use and further improve procedure efficiency and release accuracy
- NMPA registration in progress

VitaFlow® IV

Transcatheter Aortic Valve Implantation System



- Inherit the technical features of this series
- focus on enhancing safety, effectiveness, and usability
- In R&D and design stage

VitaFlow ® BE

Transcatheter Aortic Valve Implantation System



Adopts a short stent design and dry tissue，equips with other unique technical features to optimize hemodynamics and maintain valve performance

- Completed all high-risk patents analysis and avoidance;
- Completed development of new scheme design which is under testing
- In R&D and design stage

Self-developed TMVR Product: FIM Study Confirming Safety and Efficacy

TMVR pain points: anchoring difficulty, LVOTO risk, LV function impairment, long learning curve…

- **World's first dry-tissue TMVR system with clinical application**
- **Dry tissue for better biocompatibility and anti-calcification properties**
- **Compatible with both trans-septal or trans-apical approaches**

- **Low profile of stent design reducing LVOTO (Left Ventricular Outflow Tract obstruction) risks**
- **Completed ~20 CU implantations with the longest 2-year follow-up, delivering excellent MR reduction results**
- **Ease-of-use and accurate positioning, device time is only 15-25 mins**

AltaValve™: Received Breakthrough and IDE Approval of FDA

TMVR pain points: anchoring difficulty, LVOTO risk, LV function impairment, long learning curve…

Product Features

- Supra-annular fit and atrial-only fixation design overcoming anchoring and fixation difficulties
- The sole known TMVR device with the unique capability of full implant retrievability post-complete deployment and prior to detachment from the TS(Trans-spetum) Delivery System
- Mitigate the risks of LVOTO or damage.
- Suitable for the vast majority of MR(Mitral Regurgitation) patients

Progress and Milestones

- Received dual FDA Breakthrough Device designations in 1H 2024, expediting the FDA review process
- Received the FDA Investigational Device Exemption (IDE) approval to conduct a new pivotal study

AltaValve
Engineered for Your Heart™

AnchorMan® LAAC and LAAA: Enrichment of Structural Heart Portfolio

AnchorMan® Left Atrial Appendage Access System

- Compatible with AnchorMan® Left Atrial Appendage Closure System, providing the femoral venous and trans-atrial septal access
- Two sizes: single curve and double curve
- The Access Sheath outer diameter is 14 Fr

NMPA approval obtained in October 2023

CE mark expected in 2025

AnchorMan® Left Atrial Appendage Closure System

- Semi-closed structure formed by the “3D folding” technology , Rounded and soft distal end:
  - combines the merits of an open and closed closure device
  - reduces damage to the LAA tissue
  - stable anchoring
- Dense NiTi alloy frame design: achieves better sealing performance
- Two deployment models: advancement and unsheathe, easier operation

NMPA approval obtained on January 5, 2024

CE mark expected in 2025

Ramp up of commercialized implantation volume

Kewei's CHD Occluder: Affordable and Profitable

➢ Product Features



ASD Occluder | VSD Occluder | PDA Occluder

- Made of nickel-titanium alloy and polyester, provides excellent **corrosion resistance and biocompatibility**
- The structure design of the occluder provides **good axial support for the lesion**

Delivery System



- **Flexibility and resistance:** provide good cross-ability and pushability, easy to reach the defect site
- **Position accuracy:** radiopaque at the tip help for real-time imaging

➢ Steady Revenue Streams

Kewei's CHD Occluder (nondegradable, without coating) is on-par with competitors in product design.

With a competitive price point, the CHD portfolio has been a constant source of overseas revenue. Sales in China expected to pick up due to price advantage under VBP.

Financial Review

Rapid Revenue Growth Coupled by Increase in Gross Profit

Revenue (RMB'000)



Gross Profit (RMB'000)



Gross Profit Margin (%)



- **Overall revenue** increased by 26.5% in 1H24, driven by continued hospital penetration of our TAVI products in the PRC; global commercialization; and revenue contribution from new product LAAO
- **Overseas revenue contribution** reached RMB8.13 mn in 1H24
- **GPM** further improved by 4.8 ppts in 1H24 thanks to our strengthened bargaining power, domestic sourcing, improved production yield rate and manufacturing efficiency

Effective Cost Control to achieve healthy and sustainable growth

Co-ordinate internal and external resources, enhancing operational efficiency, and driving the business to achieve healthy and sustainable growth.

Our operational expenses[1] vs revenue ratio decreased by 36.9 percent points from 127.4% in 1H 2023 to 90.5% in 1H 2024.

R&D Expenses (RMB'000)

% of revenue

62.1% → 37.2%

- Based on the market outlook and input-output efficiency, evaluated and adjusted the priority and resource input in a prudent manner



Distribution Expenses (RMB'000)

% of revenue

49.2% → 39.1%

- Coordinated internal and external resources, and enhancing operational efficiency



Administrative Expenses (RMB'000)

% of revenue

16.2% → 14.2%

- Increased by 3.2 million due to the increase in amortization cost of shares granted under the approved ESOP



1. *Refers to the total amount of research and development, distribution and administrative expenses as percentage of revenue.*

Sufficient Cash Reserve for Future Development

Cash Outflow from Operating Activities

(RMB'000)



Cash and Cash Equivalents*

(RMB'000)



We maintained sufficient cash balance as of 30, Jun 2024 of RMB1.56 billion*, which can support us to strengthen our product pipelines, to improve our production capacity and further commercialization, till break-even.

*Including pledged and time deposits

Appendix

Appendix 1: Overview of Product Pipeline

	Product		
Aortic valve products	VitaFlow® System	VitaFlow®	Launched Successfully registered in Argentina and Thailand
		Alwide® balloon catheter*	Launched Successfully registered in Argentina and Thailand
	VitaFlow Liberty® System	VitaFlow Liberty® *(Retrievable)* ★	Launched Received CE Mark, registered in Argentina, Colombia, Thailand, Russia, Indonesia, HKSAR, Chili and Saudi Arabia
		★	registration in emerging markets in progress
		Angelguide® tip-preshaped super stiff guidewire*	Launched Successfully registered in Argentina, Colombia, and Brazil
	VitaFlow Liberty® Flex *(Steerable delivery system)* ▲★		NMPA Registration in progress
	VitaFlow® IV *(Lower profile, better durability and hydrodynamic properties)* ★		Design stage
	VitaFlow® Balloon Expandable *(New anti-calcification technology)*		Design stage
Mitral valve products	Self-developed replacement product ★		FIM Study
	AltaValve – Replacement product ★		FIM Study
	(Partnership with 4C Medical – commercialization rights in China) ★		Received breakthrough and IDE approval of FDA
Tricuspid valve products	Self-developed replacement product		Design stage
	Replacement product *(Partnership with 4C Medical)*		Design stage
Procedural accessories	Alwide® Plus balloon catheter ★		Successfully registered in Argentina, Colombia, Brazil, Thailand, Russia, Saudi Arabia, Indonesia and HKSAR
	★		CE Marking registration and registration in emerging markets in progress
	AccuSniper™ double-layer balloon catheter ★		Received NMPA approval
	Alpass® catheter sheath II ▲		NMPA Registration in progress
Left Atrial Appendage products	AnchorMan® Left Atrial Appendage Access System ★		Received NMPA approval
	★		CE Marking registration in progress
	AnchorMan® Left Atrial Appendage Closure System ★		Received NMPA approval
	★		CE Marking registration in progress

China status Global status

★ Major Progress during the Reporting Period

▲ Among our product candidates, these devices are exempted from clinical trial requirements in accordance with the Catalogue of Medical Device Exempted from Clinical Trials promulgated by the NMPA, as amended

* These procedural accessories are registered and commercialized offered as part of VitaFlow® or VitaFlow Liberty® system and are not registered as standalone product in China

Appendix 2: TAVI Products - Clinical Data Comparison

Company	Product	30-day mortality rate[1]	30-day major (disabling) stroke[1]	1-year mortality rate[1]	1-year major (disabling) stroke[1]	1-year moderate to severe PVL rate	1-year major vascular complications	2-year mortality rate[1]	2-year major (disabling) stroke[1]	3-year mortality rate[1]	3-year major (disabling) stroke[1]	4-year mortality rate	4-year major (disabling) stroke[1]	5-year mortality rate	5-year major (disabling) stroke	6-year mortality rate	6-year major (disabling) stroke	7-year mortality rate	7-year major (disabling) stroke	8-year mortality rate
MicroPort 心通医疗	VitaFlow®	0.9%	0.0%	2.7%	0.0%	0.0%	2.7%	4.6%	0.0%	10.9%	1.8%	12.7%	2.0%	18.2%	2.1%	26.4%	3.4%	32.7%	4.9%	39.1%
	VitaFlow Liberty®	5.0%	0.0%*	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
启明医疗 VENUSMEDTECH	VenusA-Valve	5.0%	1.0%	6.0%	1.0%	4.2%	6.1%	11.6%	N/A	17.4%	N/A	26.7%	N/A	34.1%	N/A	38.2%	N/A	47.7%	N/A	N/A
	VenusA-Plus	4.8%	1.6%	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
JC Medical	J-Valve	4.7%	0.0%	5.6%	2.0%	1.1%	N/A	9.1%	2.0%	10.8%	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Medtronic	CoreValve (U.S Pivotal)	3.3%	3.9%	14.2%	5.8%	6.1%	6.2%	22.2%	6.8%	32.9%	8.1%	N/A	N/A	55.3%	12.3%	N/A	N/A	N/A	N/A	N/A
	CoreValve（NOTION low risk）	2.1	N/A	4.9%	N/A	N/A	N/A	8.0%	N/A	N/A	N/A	N/A	N/A	N/A	N/A	42.5%	N/A	N/A	N/A	N/A
Edwards	SAPIEN 3 (U.S. Trial)	2.2%	0.9%*	14.4%	2.4%*	2.7%	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
	SAPIEN 3 (China Trial)	0.0%	2.0%*	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
	PARTNER-1	N/A	N/A	24.2%	N/A	N/A	11.6%	N/A	N/A	N/A	N/A	N/A	N/A	67.8%	N/A	N/A	N/A	N/A	N/A	N/A
PEIJIA 沛嘉医疗	TaurusOne	1.7%	N/A	6.7%	N/A	1.0%	4.2%	10%	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
	TaurusElite	2.5%	0.0%	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Note: [1] The data is from pivotal clinical trial of corresponding products and not head-to-head clinical results. VitaFlow® (N=110), VitaFlow Liberty™ (N=60), VenusA-Valve (N=101), Venus A-Plus (N=62), J-Valve (N=107), TaurusOne (N=120), TaurusElite (N=81), CoreValve (N, TAVI =391), SAPIEN 3 China trial (N=50), U.S. trial (N=583), NOTION (N, TAVI=145), PARTNER-1 (n=348).

*: The data marked with * represent the incidences of disabling stroke

Appendix 3: Product Features - TAVI

Category	Product	Features	Progress
TAVI *5 products* *2 launched*	**VitaFlow®III Self-Expanding** 	✦ Improved coaxial release to reduce PVL (Perivalvular leakage) and valve migration risks ✦ Decreased vascular complications ✦ The world's only retrievable steering motorized delivery system with improved stability and precision ✦ Improved usability and safety to prevent excessive release caused by misoperation	✦ **NMPA Registration in progress** ✦ Approval expected in 2024
	VitaFlow® IV	✦ Inherit the technical features of VitaFlow® series, such as controllable bending, full retrievability, and strong support ✦ Improvement in terms of profile, durability, and hydrodynamics ✦ Focus on enhancing safety, effectiveness, and usability ✦ To provide patients with both reliable and affordable products	✦ In R&D and design stage
	VitaFlow® Balloon Expandable 	✦ Short stent design, dry tissue ✦ Optimize hemodynamics and maintain valve performance	✦ In R&D and design stage
Procedural Accessories *6 products* *4 launched*	**AccuSniper™ Double-Layer Balloon Catheter**	✦ More stable position during inflation ✦ High burst pressure suits for severe calcification conditions ✦ The world's only double-layer balloon catheter with excellent release stability and puncture resistance	✦ Received NMPA approval in 2023

Note: The above chart is not exhaustive of all our TAVI and procedural accessory products.

Appendix 3: Product Features - TMVR

Category	Product	Features	Progress
TMVR**	**TMVR product** (In-house development)	✦ Low profile of stent design reducing LVOTO (Left Ventricular Outflow Tract obstruction) risks ✦ Dry tissue for better biocompatibility and anti-calcification properties ✦ Compatible with both trans-septal or trans-apical approaches	✦ Completed **8** CU cases by the end of June, with a total of **~20,** achieved successful at least two-year postoperative follow-up ✦ FIM study
	 **AltaValve** (Partnership with 4C) ALTAVALVE Engineered for Your Heart	✦ Supra-annular fit and atrial-only fixation design overcoming anchoring and fixation difficulties ✦ The sole known TMVR device with the unique capability of full implant retrievability post-complete deployment and prior to detachment from the TS(Trans-spetum) Delivery System ✦ Mitigate the risks of LVOTO or damage. ✦ Suitable for the vast majority of MR(Mitral Regurgitation) patients	✦ FIM study ✦ **Received breakthrough and IDE approval of FDA**

*Note: ** refers to **Transcatheter Mitral Valve Replacement**.*

Appendix 3: Product Features - TTV

Category	Product	Features	Progress
TTVR*	**TTVR product (In-house development)**	✦ Minimized postoperative complications due to oversizing by reducing radial support. ✦ Effective control of postoperative tricuspid regurgitation ✦ Simplified operation of the delivery system, with better ease of use and low learning curve	✦ In R&D and design stage
	TTVR product (Partnership with 4C)	✦ Supra-annular fit and atrial-only fixation	✦ In R&D and design stage

*Note: * refers to **Transcatheter Tricuspid Valve Replacement**.*

Appendix 3: Product Features - Left Atrial Appendage Products

Category	Product	Features	Progress
Left Atrial Appendage Products *2 launched 1 in R&D*	**AnchorMan® Left Atrial Appendage Closure (LAAC) System** 	✦ Semi-closed structure formed by the 12 “3D folding” units and the frame: • combines the merits of an open and closed closure device • solves the clinical pain point that the access sheath of the traditional plug-in closure device must deep into the LAA • stable anchoring ✦ Rounded and soft distal end: reduces damage to the LAA tissue ✦ Dense NiTi alloy frame design: allows very tight conformity to the anatomy of LAA and achieves better sealing performance ✦ Two deployment models: advancement and unsheathe, providing more options for physicians	✦ **NMPA approval received in January 2024** ✦ **CE mark expected in 2025**
	AnchorMan® Left Atrial Appendage Access System	✦ Compatible with AnchorMan® LAAC System, providing the femoral venous and trans-atrial septal access ✦ Two sizes: single curve and double curve, featuring distinct distal tip configurations for easy navigation into the LAA ✦ The Access Sheath outer diameter and inner diameter are 14 Fr and 12 Fr respectively. The reinforced access sheath has high proximal kink resistance performance. The distal end of access sheath contains 4 radiopaque marker bands for guiding precise placement for AnchorMan® LAAC System.	✦ NMPA approval received in October 2023 ✦ **CE mark expected in 2025**
	Next generation LAAC System	✦ Steerable access system to optimize coaxiality and simpler operation. ✦ Thrombi resistance coating on fabric to reduce the risk of device related thrombus.	✦ In R&D and design stage

MicroPort™
心通医疗

Our Mission

To provide trustworthy and universal access to state-of-the-art total solutions to treat structural heart diseases